Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tonya King-Charlton

Nurse Practitioner, Psychiatric/Mental Health Tampa, FL Nurse Practitioner

NPI 1144756586 CMS profile 10467996

5707 N 22Nd St, Tampa, FL 33610

Open in the dashboard

General payments

$30,613

147 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tonya King-Charlton of Tampa, FL is reported in the CMS Open Payments database as having received $30,613 across 147 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,425 5
2024 General $4,797 17
2023 General $12,983 56
2022 General $6,728 31
2021 General $679 38

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tonya King-Charlton
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Tonya King-Charlton were reported at $5,425. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Tonya King-Charlton Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $679 $166 $54–$482 $132
2022 $6,728 $195 $66–$559 $149
2023 $12,983 $233 $82–$673 $160
2024 $4,797 $236 $84–$688 $164
2025 $5,425 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AstraZeneca Pharmaceuticals LP $25,375 14 payments
  2. AstraZeneca UK Limited $2,400 2 payments
  3. Otsuka America Pharmaceutical, Inc. $640 22 payments
  4. Janssen Pharmaceuticals, Inc $528 27 payments
  5. Teva Pharmaceuticals USA, Inc. $516 26 payments
  6. AbbVie, Inc. $365 17 payments
  7. Alkermes, Inc. $346 17 payments
  8. ITI, Inc. $160 9 payments
  9. Indivior Inc. $100 5 payments
  10. Vanda Pharmaceuticals Inc. $79 4 payments
  11. Other $104 4 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Consulting Fee $27,775 16 payments
  2. Food and Beverage $2,691 129 payments
  3. Education $147 2 payments
Products named General payments · program years 2021–2025
  1. TEZSPIRE $26,275 14 payments
  2. INVEGA SUSTENNA $528 27 payments
  3. ABILIFY MAINTENA $403 18 payments
  4. VRAYLAR $365 17 payments
  5. INVEGA TRINZA $306 21 payments
  6. AUSTEDO $275 5 payments
  7. LYBALVI Cns $266 8 payments
  8. REXULTI $237 4 payments
  9. UZEDY $221 18 payments
  10. LYBALVI Cns $217 5 payments
  11. Other $1,814 103 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

876

Median for Nurse Practitioner: 389

Drug cost

$103,547

Median for Nurse Practitioner: $21,885

Branded share of claims

11.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 14 $39,227
Abilify Maintena Aripiprazole Brand 12 $36,153
Vraylar Cariprazine Hcl Brand 11 $16,779
Quetiapine Fumarate Generic 68 $1,202
Olanzapine Generic 53 $1,176
Trazodone Hcl Generic 63 $889
Buspirone Hcl Generic 76 $776
Hydroxyzine Hcl Generic 22 $770
Hydroxyzine Pamoate Generic 45 $763
Aripiprazole Generic 33 $752

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 2 billing codes

Paid by Medicare

$2,663

Medicare's payments for the services billed

Medicare patients

22

Average age 70

Services billed

34

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 75%
High blood pressure 73%
Arthritis 59%
Ischemic heart disease 50%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $4,380
$4,380 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $112
$112 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $63
$63 — —
ABILIFY ASIMTUFII
  • Otsuka America Pharmaceutical, Inc. $56
$56 — —
ABILIFY MAINTENA
  • Otsuka America Pharmaceutical, Inc. $56
$56 12 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

147 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record